推荐产品
形式
liquid
包装
pkg of 1 × 1 mL (870601C-1mg)
制造商/商品名称
Avanti Polar Lipids 870601C
浓度
1 mg/mL (870601C-1mg)
运输
dry ice
储存温度
−20°C
SMILES字符串
[O-]P(OCC[N+](C)(C)C)(OC[C@]([H])(OC(CCCCCCCC(O)=O)=O)COCCCCCCCCCCCCCCCC)=O
InChI
1S/C33H66NO9P/c1-5-6-7-8-9-10-11-12-13-14-15-16-20-23-27-40-29-31(30-42-44(38,39)41-28-26-34(2,3)4)43-33(37)25-22-19-17-18-21-24-32(35)36/h31H,5-30H2,1-4H3,(H-,35,36,38,39)/t31-/m1/s1
InChI key
ZDFOCDTXDPKJKA-WJOKGBTCSA-N
一般描述
1-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine (Azelaoyl-PAF) Azelaoyl-PAF is an alkyl phosphatidylcholine and is a component of the lipid pool within oxidized low-density lipoprotein (oxLDL) particles. Azelaoyl-PAF is a low molecular weight phospholipid.
应用
Azelaoyl-PAF may be used in binding assay of anti-inflammatory peptides, 2F and 4F.
生化/生理作用
1-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine (Azelaoyl-PAF) acts as an agonist for peroxisome proliferator-activated receptors γ(PPAR-γ). It may be used as a therapeutic for Friedreich′s ataxia (FRDA). At low concentrations azelaoyl-PAF may induce apoptosis.
包装
5 mL Clear Glass Sealed Ampule (870601C-1mg)
警示用语：
Danger
危险分类
Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3
靶器官
Central nervous system, Liver,Kidney
WGK
WGK 3
法规信息
危险化学品
易制毒化学品（2类）
Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids
Epand RF, et al.
Biochimica et Biophysica Acta - Biomembranes, 1788(9), 1967-1975 (2009)
PPAR-gamma agonist azelaoyl PAF increases frataxin protein and mRNA expression. New implications for the friedreich?s ataxia therapy
Marmolino D, et al.
Cerebellum, 8(2), 98-103 (2009)
S S Davies et al.
The Journal of biological chemistry, 276(19), 16015-16023 (2001-03-30)
Synthetic high affinity peroxisome proliferator-activated receptor (PPAR) agonists are known, but biologic ligands are of low affinity. Oxidized low density lipoprotein (oxLDL) is inflammatory and signals through PPARs. We showed, by phospholipase A(1) digestion, that PPARgamma agonists in oxLDL arise
Douglas S Watson et al.
Vaccine, 27(34), 4672-4683 (2009-06-13)
The membrane proximal region (MPR) of HIV-1 gp41 is a desirable target for development of a vaccine that elicits neutralizing antibodies since the patient-derived monoclonal antibodies, 2F5 and 4E10, bind to the MPR and neutralize primary HIV isolates. The 2F5
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门